PITTSBURGH--(BUSINESS WIRE)--CardiacAssist Inc., a growing and profitable medical device company, announced today that it will exhibit its TandemHeart® System in San Francisco at the Society of Thoracic Surgeons (STS) 45th Annual Meeting that begins next week. The TandemHeart is the only 5 lpm net flow, percutaneous “extracorporeal circulatory support” device approved by the FDA for sale in the U.S. All other heart assist devices—including Impella 2.5—are labeled by the FDA to be used for “partial circulatory support” with less than 2.5 lpm net flow. The TandemHeart device can be placed rapidly in the cath lab or operating room, providing effective, reliable, temporary circulatory support for critically ill patients.
